AstraZeneca returns to China’s CSPC for $4.7B obesity deal - Fierce Biotech

2026-01-30 - 10:15

AstraZeneca returns to China’s CSPC for $4.7B obesity deal Fierce Biotech

Share this post:

← Back to feed